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Abstract 
AIM: To evaluate the efficacy of imiquimod 5% in periungual wart treatment. 
MATERIAL AND METHODS: A group of 40 patients were recruited to apply imiquimod 5 % cream once daily for 
5 consecutive days per week in 8 weeks. They were classified into 3 levels: Mild (the total lesion area ≤ 25 mm
2
), 
moderate (25 mm
2
 <total lesion area ≤ 50 mm
2
), severe (total lesion area > 50 mm
2
). The outcome was evaluated 
at the 4
th
 and the 8
th
 week. The result was graded as excellent (complete clearance), good (≥ 50% clearance) and 
poor (< 50% clearance).  
RESULTS: The total area of the wart lesion got decreased significantly from the beginning to the 4
th
 and the 8
th
 
week (36.7 mm
2
 vs 16.8 mm
2
, p = 0.0001 and 16.8 mm
2
 vs 8.8 mm
2
, p = 0.01). The complete clearance rate at 
the 4th week was lower than that at the 8th week significantly (22.5% vs 72.5%, p = 0.04). The clearance rate of 
patients suffering severe warts was lower significantly than that of mild/ moderate patients (82.8% vs 45.5%, p = 
0.03). The duration of the disease in people who responded completely to imiquimod was shorter than that of 
patients partially responded (10.2 ± 14.1 months vs 22.3 ± 14.3 months, p = 0.02). Adverse effects were not 
common, mild and local only. Recurrence rate after 6 months of follow up was 3.5%.  
CONCLUSION: In conclusion, Imiquimod 5% cream is a safe and effective drug in the treatment of periungual 
warts. 
 
 
 
 
 
 
Introduction 
 
Periungual warts a common skin disease and 
can interfere with nails development, mainly in 
immunosuppressed patients [1], [2].  
Tissue destruction therapy is painful, and the 
recurrence is frequent. Imiquimod is a topical 
immunosuppressive agent, which stimulates the 
production of inflammatory cytokines that activate and 
maintain cell-mediated immune response [3]. 
This study aimed to evaluate the efficacy of 
imiquimod 5%, once daily for 5 consecutive days per 
week, in periungual wart treatment in 40 Vietnamese 
patients, including 19 females (aged 20.4 ± 13.8) and 
21 males (aged 27.3 ± 13.5) patients.  
Material and Methods 
 
A group of 40 patients were recruited to apply 
imiquimod 5 % cream once daily for 5 consecutive 
days per week in 8 weeks. They were classified into 3 
levels: Mild (the total lesion area ≤ 25 mm
2
), moderate 
(25 mm
2
 <total lesion area ≤ 50 mm
2
), severe (total 
lesion area > 50 mm
2
).  
The outcome was evaluated at the 4th and 
the 8th week.  
The result was graded as excellent (complete 
clearance), good (≥ 50% clearance) and poor (< 50% 
clearance). 
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Results 
 
The warts condition before the treatment was 
mild in 21 patients (52.5%) (the total lesion area ≤ 25 
mm
2
), moderate in 8 patients (20.0%) (25 mm
2
 <total 
lesion area ≤ 50 mm
2
) and severe in 11 patients 
(27.5%) (total lesion area > 50 mm
2
). The duration of 
disease was 13.5 ± 15.0 months.  
 
Figure 1: Wart area (in mm
2
) change by the time 
 
The total area of warts got decreased 
significantly from 36.7mm
2
 at week 0 to 16.8 mm
2
 at the 
4
th
 week and 8.8 mm
2
 at the 8
th
 week (p < 0.05) as 
shown in Figure 1. The excellent outcome at the 8
th 
week was higher than that at the week 4
th 
significantly 
(72.5% vs 22.5%, p = 0.04). The complete clearing 
rate at the 8
th 
week was significantly higher than that 
at the 4
th 
week due to the slow effect of imiquimod in 
stimulating immune cells. 
 
Figure 2: Periungual warts before (A) and after (B) treatment with 
imiquimod 5 % cream 
 
An excellent outcome was seen in 68.2% of 
people who had got treated by other modalities before 
applying imiquimod and 77.8% of naïve patients, the 
difference was not significant (p = 0.37, Fisher exact 
test) (Table 1). 
Table 1: Treatment outcomes and related factors 
Outcomes N 
Wart 
duration 
(m ± SD) P 
 
Wart severity at the 
beginning 
P 
Treatment before 
imiquimod 
P 
Severe 
Mild/ 
moderate 
Yes No 
N % N % N % N %  
Excellent 29 10.2 ± 14.1 
0.02 
5 45.5 24 82.8 
0.03 
15 68.2 14 77.8 
0.37* 
Good/poor 11 22.3 ± 14.3 6 54.5 5 17.2 7 31.8 4 22.2 
*: Fisher’s exact test.  
 
No systemic side effects have been reported. 
Local side effects had been seen in 37.5% patients, 
but 73.33% of the side effect was mild.  
After 6 months of follow-up, there was only 
one relapse case (3.5%) after 3 months.  
 
 
Discussion 
 
Excellent results in a group of patients 
suffering mild/moderate wart were higher than that of 
the group having severe wart (82.8% vs 45.5%, p = 
0.03). So longer the duration of disease was, the less 
effective the treatment modality was [4], [5], [6].  
There was only one relapse case after 3 
months. It could be explained by the ability of 
imiquimod cream that can start and maintain HPV 
specific cell-mediated immunity [7], [8], [9], [10].  
In conclusions, Imiquimod 5% cream is safe 
and effective drug in the treatment of periungual 
warts. Early treatment leads to better results.  
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